S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
How will EU ban and West's price cap on Russian diesel work?
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
How will EU ban and West's price cap on Russian diesel work?
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
How will EU ban and West's price cap on Russian diesel work?
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
How will EU ban and West's price cap on Russian diesel work?
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
NASDAQ:XFOR

X4 Pharmaceuticals - XFOR Stock Forecast, Price & News

$1.04
0.00 (0.00%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.01
$1.07
50-Day Range
$0.69
$1.85
52-Week Range
$0.65
$2.41
Volume
658,543 shs
Average Volume
768,538 shs
Market Capitalization
$72.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.86

X4 Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
559.3% Upside
$6.86 Price Target
Short Interest
Healthy
1.81% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.43) to ($0.83) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.74 out of 5 stars

Medical Sector

38th out of 1,028 stocks

Biological Products, Except Diagnostic Industry

8th out of 168 stocks

XFOR stock logo

About X4 Pharmaceuticals (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

Receive XFOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XFOR Stock News Headlines

What Makes X4 Pharmaceuticals (XFOR) a New Buy Stock
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
X4 Pharmaceuticals
XFOR X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals Prices $65.0 Million Public Offering
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
X4 Pharmaceuticals: Q3 Earnings Insights
See More Headlines
Receive XFOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XFOR Company Calendar

Last Earnings
11/04/2021
Today
2/05/2023
Next Earnings (Estimated)
3/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XFOR
Fax
N/A
Employees
83
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.86
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+559.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-88,700,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3 million
Book Value
$2.61 per share

Miscellaneous

Free Float
2,839,000
Market Cap
$72.01 million
Optionable
Not Optionable
Beta
0.50

Key Executives

  • Paula S. RaganPaula S. Ragan
    President, Chief Executive Officer & Director
  • Mary DiBiase
    Chief Operating Officer
  • Adam S. MostafaAdam S. Mostafa
    Chief Financial Officer & Treasurer
  • Murray W. Stewart
    Independent Director & Chief Medical Officer
  • Art Taveras
    Chief Scientific Officer













XFOR Stock - Frequently Asked Questions

Should I buy or sell X4 Pharmaceuticals stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XFOR shares.
View XFOR analyst ratings
or view top-rated stocks.

What is X4 Pharmaceuticals' stock price forecast for 2023?

5 brokers have issued 12-month price objectives for X4 Pharmaceuticals' stock. Their XFOR share price forecasts range from $3.00 to $10.00. On average, they anticipate the company's stock price to reach $6.86 in the next twelve months. This suggests a possible upside of 559.3% from the stock's current price.
View analysts price targets for XFOR
or view top-rated stocks among Wall Street analysts.

How have XFOR shares performed in 2023?

X4 Pharmaceuticals' stock was trading at $0.9930 at the start of the year. Since then, XFOR stock has increased by 4.7% and is now trading at $1.04.
View the best growth stocks for 2023 here
.

Are investors shorting X4 Pharmaceuticals?

X4 Pharmaceuticals saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 1,250,000 shares, a decrease of 20.9% from the December 31st total of 1,580,000 shares. Based on an average trading volume of 1,270,000 shares, the short-interest ratio is presently 1.0 days.
View X4 Pharmaceuticals' Short Interest
.

When is X4 Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our XFOR earnings forecast
.

How were X4 Pharmaceuticals' earnings last quarter?

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by $0.04. During the same quarter last year, the company earned ($0.87) EPS.

What other stocks do shareholders of X4 Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), AbbVie (ABBV), Flexion Therapeutics (FLXN), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

What is X4 Pharmaceuticals' stock symbol?

X4 Pharmaceuticals trades on the NASDAQ under the ticker symbol "XFOR."

Who are X4 Pharmaceuticals' major shareholders?

X4 Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adam S Mostafa, Adam S Mostafa, Derek M Meisner, Derek M Meisner, Paula Ragan and Renato Skerlj.
View institutional ownership trends
.

How do I buy shares of X4 Pharmaceuticals?

Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is X4 Pharmaceuticals' stock price today?

One share of XFOR stock can currently be purchased for approximately $1.04.

How much money does X4 Pharmaceuticals make?

X4 Pharmaceuticals (NASDAQ:XFOR) has a market capitalization of $72.01 million and generates $3 million in revenue each year. The company earns $-88,700,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis.

How can I contact X4 Pharmaceuticals?

X4 Pharmaceuticals' mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The official website for the company is www.x4pharma.com. The company can be reached via phone at (857) 529-8300 or via email at ir@arsanis.com.

This page (NASDAQ:XFOR) was last updated on 2/5/2023 by MarketBeat.com Staff